By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Lymphoproliferative Disorders are discussed in a new report. According to news reporting originating in Morgantown, West Virginia, by NewsRx journalists, research stated, "Modern chemoimmunotherapies have produced higher response rates and improved survival in mantle cell lymphoma (MCL); however, disease relapse remains a challenge. The availability of various post-remission maintenance or consolidation strategies, have led some to question the role of upfront autologous hematopoietic cell transplantation (auto-HCT) consolidation for MCL, in the chemoimmunotherapy-era."
The news reporters obtained a quote from the research from West Virginia University, "A one size fits all approach is no longer appropriate for MCL in first remission, and the choice of preferred post-remission (observation, maintenance or consolidation) strategy is increasingly becoming a factor of patient age, comorbidities and disease risk stratification. In select low-risk patients (based on Mantle cell lymphoma International Prognostic Index (MIPI)), observation following rituximab plus Hyper-CVAD-like inductions seems appropriate. Rituximab maintenance after anthracycline-based chemoimmunotherapies in elderly transplant ineligible patients has shown survival benefit and should be considered a valid option. Limited studies suggest feasibility of radioimmunotherapy consolidation in first remission; however, in the absence of randomized data, this modality remains investigational. In younger, transplant-eligible patients receiving cytarabine-containing inductions, upfront consolidation with auto-HCT has shown survival benefit, and remains a standard-of-care option in the modern-era. Hyper-CVAD associated stem cell mobilization failure is an increasingly recognized problem, underscoring the need for alternative inductions, or consideration for early stem cell collection, when this induction regimen is used. Outcomes of high-risk MIPI patients remain suboptimal with currently available induction and post-remission strategies and represents an area where adoptive immunotherapy in the form of allogeneic-HCT warrants investigation."
According to the news reporters, the research concluded: "Incorporation of novel MoAbs and targeted agents (PI3K inhibitors, mTOR inhibitors, BTK inhibitors and so on.) in maintenance and consolidation strategies will build on the significant therapeutic gains of last decade, in coming years."
For more information on this research see: Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? Bone Marrow Transplantation, 2013;48(12):1489-1496. Bone Marrow Transplantation can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Bone Marrow Transplantation - www.nature.com/bmt/)
Our news correspondents report that additional information may be obtained by contacting L. Chaudhary, West Virginia University, Myeloma & Lymphoma Serv, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506, United States. Additional authors for this research include M.A. Kharfan-Dabaja, P. Hari and M. Hamadani (see also Lymphoproliferative Disorders).
Keywords for this news article include: Antineoplastic Monoclonal Antibodies, Antirheumatics, Biotechnology, Drugs, Surgery, Oncology, Rituximab, Morgantown, Hematology, Radiotherapy, West Virginia, United States, Hematopoietic, Medical Devices, Immunomodulation, Lymphatic Diseases, Radioimmunotherapy, Cell Transplantation, Lymphoma Gene Therapy
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC